Juvenile Myelomonocytic Leukemia (JMML)
Overview
Juvenile Myelomonocytic Leukemia (JMML) is a rare, aggressive myeloproliferative disorder that primarily affects infants and young children. Unlike most childhood leukemias, which are lymphoid in origin, JMML originates from the myeloid line of blood cells and is characterized by an uncontrolled proliferation of monocytes and granulocyte‑precursor cells.[1][2]
Who it affects: The disease almost exclusively occurs in children under 5 years of age, with a median diagnosis age of 2 years. It is slightly more common in males than females (approximately 1.3 : 1).[3]
Prevalence: JMML accounts for 0.5‑1 % of all pediatric leukemias. The annual incidence in the United States is estimated at 1–2 new cases per million children, translating to roughly 30–40 diagnoses each year nationwide.[4]
Symptoms
The clinical picture of JMML can be variable and often mimics infections or other benign conditions, which can delay diagnosis. Common symptoms include:
- Fever and night sweats: Persistent low‑grade fever without a clear source.
- Unexplained weight loss: Often accompanied by poor appetite.
- Fatigue and lethargy: Children may become unusually sleepy or irritable.
- Enlarged spleen (splenomegaly): The most frequent physical finding; the abdomen may feel firm or the child may complain of abdominal fullness.
- Enlarged liver (hepatomegaly): May coexist with splenomegaly and cause mild jaundice.
- Petechiae or bruising: Due to low platelet counts (thrombocytopenia).
- Easy bleeding: Nosebleeds, gum bleeding, or prolonged bleeding from minor cuts.
- Frequent infections: Low neutrophil counts (neutropenia) predispose to bacterial or viral infections.
- Skin rash or infiltrates: Sometimes a pinkish “leukemia cutis” rash appears.
- Respiratory distress: Enlarged spleen can press on the diaphragm, leading to shortness of breath.
- Bone pain or joint discomfort: Though less common, excess myeloid cells can infiltrate bone marrow.
Causes and Risk Factors
JMML is not linked to environmental exposures or lifestyle choices; it arises primarily from genetic aberrations that affect signaling pathways controlling blood cell growth.
Genetic causes
- RAS pathway mutations: Somatic (acquired) mutations in NRAS or KRAS genes are found in ≈ 30 % of cases.
- NF1 (Neurofibromatosis type 1): Children with NF1 have a 200‑fold increased risk; JMML may be the first sign of NF1.[5]
- PTPN11 mutations: Germline or somatic changes in the PTPN11 gene (encoding SHP‑2) cause ≈ 35 % of sporadic JMML and are the hallmark of Noonan‑like syndrome with JMML.[6]
- CBL mutations: Present in about 10 % of cases; often associated with a milder clinical course.
- GATA2 deficiency: Rare, but predisposes to JMML and other myelodysplastic syndromes.
Who is at higher risk?
- Children with known NF1, Noonan syndrome, or other RASopathies.
- Infants with a family history of JMJM (extremely rare hereditary forms).
- Male children (slightly higher incidence).
Diagnosis
Because JMML symptoms overlap with many benign pediatric conditions, a systematic work‑up is essential.
Initial laboratory evaluation
- Complete blood count (CBC) with differential: Typically shows leukocytosis (high white‑blood‑cell count) with a left shift, monocytosis (≥ 1 × 10⁹/L), anemia, and thrombocytopenia.
- Peripheral blood smear: Reveals dysplastic myeloid precursors and increased blasts (< 20 %).
- Serum lactate dehydrogenase (LDH) and uric acid: Often elevated due to rapid cell turnover.
Confirmatory tests
- Bone marrow aspirate and biopsy: Shows hypercellular marrow with monocytic proliferation, < 20 % blasts, and absence of the Philadelphia chromosome (BCR‑ABL1).
- Cytogenetic & molecular studies:
- Fluorescence in situ hybridization (FISH) for PDGFRB, FGFR1 rearrangements (to rule out other myeloproliferative neoplasms).
- Next‑generation sequencing (NGS) panel targeting RAS‑pathway genes (NRAS, KRAS, PTPN11, CBL, NF1).
- Flow cytometry: Identifies abnormal myeloid immunophenotype (CD14⁺, CD33⁺, CD45⁺dim).
- GM‑CSF hypersensitivity assay: In vitro colony‑forming assay; JMML cells grow excessively in response to granulocyte‑macrophage colony‑stimulating factor. This test is highly specific but less commonly performed in modern centers.
Diagnostic criteria (per WHO 2022)
A diagnosis of JMML is made when ALL of the following are present:
- Peripheral blood monocytosis ≥ 1 × 10⁹/L.
- Fewer than 20 % blasts in blood or bone marrow.
- Absence of the BCR‑ABL1 fusion gene.
- Presence of one or more of the following:
- RAS‑pathway mutation (NF1, NRAS, KRAS, PTPN11, CBL).
- Chromosomal abnormalities (e.g., monosomy 7, trisomy 8).
- Hyper‑responsive myeloid progenitors to GM‑CSF.
Treatment Options
JMML is aggressive; the only curative therapy is hematopoietic stem‑cell transplantation (HSCT). Other treatments aim to control disease while a donor is identified.
1. Hematopoietic Stem‑Cell Transplantation (HSCT)
- Allogeneic HSCT: Bone‑marrow, peripheral‑blood stem cells, or umbilical‑cord blood from an HLA‑matched sibling or unrelated donor. Event‑free survival rates range from 50‑70 % with modern reduced‑intensity conditioning regimens.[7]
- Reduced‑intensity conditioning (RIC): Uses lower doses of chemotherapy/radiation to reduce transplant‑related toxicity, especially important for infants.
- Post‑transplant monitoring: Chimerism studies, regular CBCs, and surveillance for graft‑versus‑host disease (GVHD).
2. Pre‑transplant “Bridge” Therapies
These aim to lower disease burden and improve transplant eligibility.
- Low‑dose cytarabine: Frequently first‑line; can achieve temporary remission in 30‑40 % of patients.
- Hydroxyurea: Controls leukocytosis and splenomegaly.
- Hypomethylating agents (Azacitidine, Decitabine): Show response rates of 30‑50 % and are increasingly used as bridge therapy.[8]
- Targeted inhibitors:
- MEK inhibitors (Trametinib, Selumetinib) – under investigation for patients with RAS‑mutant JMJM.
- JAK inhibitors (Ruxolitinib) – limited data, used in compassionate protocols.
3. Supportive Care
- Transfusion support (red‑cell and platelet transfusions) for symptomatic anemia or thrombocytopenia.
- Antibiotic/antifungal prophylaxis during periods of neutropenia.
- Growth factor avoidance: Recombinant GM‑CSF is contraindicated because it can worsen JMML.
- Management of splenomegaly‑related discomfort (e.g., low‑dose steroids, occasional radiation).
4. Clinical Trials
Because JMML is rare, enrollment in research protocols (e.g., novel MEK inhibitors, CAR‑T targeting myeloid antigens) is strongly encouraged when available.
Living with Juvenile Myelomonocytic Leukemia
Beyond medical treatment, families face daily challenges. Below are practical tips to help maintain quality of life.
Medical Follow‑up
- Schedule regular hematology appointments (every 2‑4 weeks during active therapy, then every 3‑6 months post‑HSCT).
- Maintain a personal health record: CBC trends, medication list, transplant details.
- Vaccinations: After HSCT, follow the immunization schedule recommended by the transplant center (often delayed until 6‑12 months post‑transplant).
Nutrition & Growth
- Work with a pediatric dietitian; high‑protein, calorie‑dense meals support growth.
- Monitor weight and height at each visit—growth hormone deficiency can occur after HSCT.
- Address feeding difficulties early (e.g., oral aversion, nausea from chemotherapy).
Infection Prevention
- Hand‑washing hygiene; avoid crowded places during periods of low neutrophils.
- Promptly treat fevers (> 38 °C) with a call to the oncology team.
- Keep a list of emergency contacts, including the transplant center’s night‑call number.
Psychosocial Support
- Seek counseling for the child and family—stress, anxiety, and depression are common.
- Connect with patient‑advocacy groups (e.g., Children’s Oncology Group, JMML Foundation).
- Consider school‑based accommodations: flexible attendance, reduced physical‑activity demands during treatment phases.
Daily Activity & School
- Light exercise (walking, gentle play) is usually safe; avoid contact sports while platelet counts are < 30 × 10⁹/L.
- Encourage normal play and routines to promote emotional well‑being.
Prevention
Because JMML is driven by genetic mutations that are mostly spontaneous or inherited, primary prevention is limited.
- Genetic counseling: Families with known NF1, Noonan syndrome, or other RASopathies should receive counseling about JMML risk.
- Prenatal testing: In families with identified germline mutations (e.g., PTPN11), prenatal or pre‑implantation genetic diagnosis can be discussed.
- Environmental factors: No clear link to radiation, chemicals, or infections; thus standard “healthy lifestyle” measures are appropriate but not specifically preventative.
Complications
If left untreated or if disease recurs after transplant, JMML can lead to serious, life‑threatening problems.
- Progression to acute myeloid leukemia (AML): Transformation occurs in ≈ 10‑15 % of untreated cases.
- Myelodysplastic syndrome (MDS): Dysplastic changes and cytopenias may develop after prolonged disease.
- Severe infections: Neutropenia predisposes to bacterial sepsis, opportunistic fungal infections, and viral reactivations.
- Hemorrhage: Thrombocytopenia can cause life‑threatening bleeding (intracranial, gastrointestinal).
- Organ infiltration: Massive splenomegaly may compress abdominal vessels, causing portal hypertension or respiratory compromise.
- Graft‑versus‑host disease (GVHD): The most common transplant‑related complication, affecting skin, liver, and gut.
- Secondary malignancies: Long‑term survivors have a modestly increased risk of solid tumors and therapy‑related leukemias.
When to Seek Emergency Care
Warning Signs That Require Immediate Medical Attention
- High fever (≥ 38.5 °C / 101.3 °F) that does not improve after 24 hours of antibiotics.
- Severe or uncontrolled bleeding (e.g., nosebleed lasting > 20 minutes, bleeding gums, blood in urine or stool).
- Sudden, severe abdominal pain or a rapidly enlarging abdomen (possible splenic rupture).
- Difficulty breathing, rapid breathing, or persistent cough.
- New onset of confusion, lethargy, or seizures.
- Unexplained bruising, petechiae covering large areas, or skin that looks purplish.
- Significant drop in platelet count (< 10 × 10⁹/L) noted on recent labs.
Call 911 or go to the nearest emergency department if any of these symptoms appear.
References
- American Cancer Society. “Juvenile Myelomonocytic Leukemia.” cancer.org. Accessed April 2026.
- National Cancer Institute. “JMML Treatment (PDQ®) – Health Professional Version.” cancer.gov. 2024.
- Children’s Oncology Group. “JMML – Clinical Trial Overview.” childrensoncologygroup.org. 2023.
- World Health Organization. “Classification of Myeloid Neoplasms.” WHO Classification, 5th edition, 2022.
- Mayo Clinic. “Neurofibromatosis type 1.” mayoclinic.org. 2025.
- Cleveland Clinic. “PTPN11 mutations and Noonan syndrome.” clevelandclinic.org. 2024.
- Jain D et al. “Allogeneic Stem Cell Transplant for JMML: Long‑Term Outcomes.” *Blood* 2022;140(5):525‑536.
- Lanino E et al. “Azacitidine as a Bridge to Transplant in JMML.” *Leukemia* 2023;37(3):532‑541.